Submission of a new form of natalizumab (Tysabri®) for RRMS to PBAC meeting March 2023

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) to support the inclusion of Shingrix® on the Pharmaceutical Benefits Scheme (PBS) for people with multiple sclerosis (MS) who are immunocompromised.